Michiko Shindo, MD, PhD; Adrian M. Di Bisceglie, MD; Ling Cheung, BA; J. Wai-Kuo Shih, PhD; Karen Cristiano, PhD; Stephen M. Feinstone, MD; Jay H. Hoofnagle, MD
Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, et al. Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C. Ann Intern Med. 1991;115:700-704. doi: 10.7326/0003-4819-115-9-700
Download citation file:
Published: Ann Intern Med. 1991;115(9):700-704.
▪ Objective: To assess the effect of alpha-interferon therapy on hepatitis C viral RNA in serum of patients with chronic hepatitis C.
▪ Design: Retrospective testing for hepatitis C viral (HCV) RNA and antibody to the hepatitis C virus (anti-HCV) of stored serum samples from a randomized, double-blind, placebo-controlled trial of alphainterferon therapy.
▪ Setting: Warren Grant Magnuson Clinical Center of the National Institutes of Health, a tertiary referral center.
▪ Patients: Forty-one patients with chronic non-A, non-B hepatitis were entered in this trial.
▪ Interventions: Twenty-one patients were treated with alpha-interferon, and 20 patients were treated with placebo for 6 months. Seventeen placebo recipients were then treated with alpha-interferon for up to 1 year.
▪ Methods: Samples were tested for anti-HCV by enzyme-linked immunosorbent assay. Hepatitis C viral RNA was detected in serum using the polymerase chain reaction. Titers of both antibody and RNA were determined by serial end-point dilution.
▪ Main Results: At entry into the trial, 37 (90%) of 41 patients had anti-HCV and 39 (95%) had HCV RNA in serum. Anti-HCV titers decreased slightly with treatment. Serum levels of HCV RNA decreased in all patients who responded to alpha-interferon therapy with improvements in serum aminotransferases; in 17 of 21 responders (81%; 95% Cl, 58% to 95%) HCV RNA became undetectable. In contrast, in only 2 of 16 (12%; Cl, 2% to 38%) patients who did not respond to treatment did HCV RNA become undetectable. In 19 patients treated during the preliminary 6-month period with placebo, HCV RNA remained detectable. Finally, in the 11 patients who relapsed when treatment was stopped, HCV RNA reappeared in the serum, but in 4 of 7 patients with a sustained improvement in serum aminotransferases, HCV RNA remained undetectable.
▪ Conclusions: These results indicate that the clinical and serum biochemical response to alpha-interferon in chronic hepatitis C is associated with a loss of detectable HCV genome from serum.
Learn more about subscription options.
Register Now for a free account.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only